{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:53:05Z","timestamp":1791255185061,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","award":["SDAP-2023-033"],"award-info":[{"award-number":["SDAP-2023-033"]}],"id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-026-15102-z","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:45:54Z","timestamp":1783748754000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Estimating stage-specific lung cancer costs for economic evaluation of LDCT screening in Ireland: a patient-level microsimulation"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4839-8081","authenticated-orcid":false,"given":"Tatiana","family":"Bezdenezhnykh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3414-7388","authenticated-orcid":false,"given":"James F.","family":"O\u2019Mahony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5680-2772","authenticated-orcid":false,"given":"Jarushka","family":"Naidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1451-0557","authenticated-orcid":false,"given":"Koen de","family":"Nijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3868-4737","authenticated-orcid":false,"given":"Deirdre","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2861-7665","authenticated-orcid":false,"given":"Seamus","family":"Cotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1119-064X","authenticated-orcid":false,"given":"Kathleen","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3929-2018","authenticated-orcid":false,"given":"Patrick","family":"Redmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"15102_CR1","doi-asserted-by":"publisher","first-page":"596","DOI":"10.3390\/cancers18040596","volume":"18","author":"G Firmani","year":"2026","unstructured":"Firmani G, Dolcini J, Chiavarini M, Barbadoro P. Lung Cancer Screening in Adults: State-of-the-Art and Policy Mapping (2025). Cancers. 2026;18:596. https:\/\/doi.org\/10.3390\/cancers18040596.","journal-title":"Cancers"},{"key":"15102_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jtho.2023.07.019","volume":"19","author":"S Lam","year":"2024","unstructured":"Lam S, Bai C, Baldwin DR, Chen Y, Connolly C, De Koning H, et al. Current and Future Perspectives on Computed Tomography Screening for Lung Cancer: A Roadmap From 2023 to 2027 From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2024;19:36\u201351. https:\/\/doi.org\/10.1016\/j.jtho.2023.07.019.","journal-title":"J Thorac Oncol"},{"key":"15102_CR3","first-page":"1","volume":"100","author":"Council of the European Union","year":"2022","unstructured":"Council of the European Union. Council Recommendation on Strengthening Prevention through Early Detection: A New EU Approach on Cancer Screening Replacing Council Recommendation 2003\/878\/EC. Off J Eur Union. 2022;100:1\u201310.","journal-title":"Off J Eur Union"},{"key":"15102_CR4","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1093\/eurpub\/ckab014","volume":"31","author":"T Albreht","year":"2021","unstructured":"Albreht T. Europe\u2019s beating cancer plan\u2014a new step towards more comprehensive and equitable cancer control in Europe. Eur J Pub Health. 2021;31:456\u20137. https:\/\/doi.org\/10.1093\/eurpub\/ckab014.","journal-title":"Eur J Pub Health"},{"key":"15102_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa1911793","volume":"382","author":"HJ De Koning","year":"2020","unstructured":"De Koning HJ, Van Der Aalst CM, De Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020;382:503\u201313. https:\/\/doi.org\/10.1056\/NEJMoa1911793.","journal-title":"N Engl J Med"},{"key":"15102_CR6","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa1312547","volume":"371","author":"WC Black","year":"2014","unstructured":"Black WC, Gareen IF, Soneji SS, Sicks JD, Keeler EB, Aberle DR, et al. Cost-Effectiveness of CT Screening in the National Lung Screening Trial. N Engl J Med. 2014;371:1793\u2013802. https:\/\/doi.org\/10.1056\/NEJMoa1312547.","journal-title":"N Engl J Med"},{"key":"15102_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12913-015-0725-3","volume":"15","author":"J Corral","year":"2015","unstructured":"Corral J, Espin\u00e0s JA, Cots F, Pareja L, Sol\u00e0 J, Font R, et al. Estimation of lung cancer diagnosis and treatment costs based on a patient-level analysis in Catalonia (Spain). BMC health services research. Springer. 2015;15:70. https:\/\/doi.org\/10.1186\/s12913-015-0725-3.","journal-title":"Springer"},{"key":"15102_CR8","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3111\/13696998.2015.1032974","volume":"18","author":"A McGuire","year":"2015","unstructured":"McGuire A, Martin M, Lenz C, Sollano JA. Treatment cost of non-small cell lung cancer in three European countries: comparisons across France, Germany, and England using administrative databases. J Med Econ. 2015;18:525\u201332. https:\/\/doi.org\/10.3111\/13696998.2015.1032974.","journal-title":"J Med Econ"},{"key":"15102_CR9","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1038\/bjc.2016.77","volume":"114","author":"M Laudicella","year":"2016","unstructured":"Laudicella M, Walsh B, Burns E, Smith PC. Cost of care for cancer patients in England: evidence from population-based patient-level data. Br J Cancer. 2016;114:1286\u201392. https:\/\/doi.org\/10.1038\/bjc.2016.77.","journal-title":"Br J Cancer"},{"key":"15102_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S1470-2045(25)00678-3","volume":"27","author":"C Pearson","year":"2026","unstructured":"Pearson C, Jones DA, Baily G, Cherry R, Gray E, Hiom S, et al. Influence of stage at cancer diagnosis on NHS hospital care costs in England: a national, retrospective, population-based cohort study using individual patient-level data. Lancet Oncol. 2026;27:361\u201371. https:\/\/doi.org\/10.1016\/S1470-2045(25)00678-3.","journal-title":"Lancet Oncol"},{"key":"15102_CR11","doi-asserted-by":"publisher","first-page":"114231","DOI":"10.1016\/j.ejca.2024.114231","volume":"208","author":"K De Nijs","year":"2024","unstructured":"De Nijs K, De Koning HJ, Van Der Aalst C, Ten Haaf K. Medical costs of lung cancer by stage, histology and first-line treatment modality in the Netherlands (2012\u20132021). Eur J Cancer. 2024;208:114231. https:\/\/doi.org\/10.1016\/j.ejca.2024.114231.","journal-title":"Eur J Cancer"},{"key":"15102_CR12","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1080\/0284186X.2023.2218040","volume":"62","author":"R-L Leskel\u00e4","year":"2023","unstructured":"Leskel\u00e4 R-L, Korhonen S, Haavisto I, Nuutinen M, Peltonen E, Herse F, et al. Trends in cost of treatment of lung cancer patients in 2014\u20132019 in Finland\u2013a descriptive register study. Acta Oncol. 2023;62:587\u201393. https:\/\/doi.org\/10.1080\/0284186X.2023.2218040.","journal-title":"Acta Oncol"},{"key":"15102_CR13","doi-asserted-by":"publisher","unstructured":"Chouaid C, Marchal C, Apert M, Bensimon L, Guimard V, N\u00e9e M, et al. Change in healthcare resource use and associated costs of patients with metastatic lung cancer between 2013 and 2021: an observational study from the French national health data system. Eur J Health Econ. 2025;1\u201311. https:\/\/doi.org\/10.1007\/s10198-025-01864-6.","DOI":"10.1007\/s10198-025-01864-6"},{"key":"15102_CR14","doi-asserted-by":"publisher","first-page":"e6659","DOI":"10.1002\/cam4.6659","volume":"13","author":"V Gorasso","year":"2024","unstructured":"Gorasso V, Vandevijvere S, Van der Heyden J, Pelgrims I, Hilderink H, Nusselder W, et al. The incremental healthcare cost associated with cancer in Belgium: A registry-based data analysis. Cancer Med. 2024;13:e6659. https:\/\/doi.org\/10.1002\/cam4.6659.","journal-title":"Cancer Med"},{"key":"15102_CR15","doi-asserted-by":"publisher","first-page":"108697","DOI":"10.1016\/j.lungcan.2025.108697","volume":"207","author":"M Neyt","year":"2025","unstructured":"Neyt M, Luyten J, Desimpel F, Camberlin C, Primus-de Jong C, Verleye L. An economic evaluation of lung cancer screening with low-dose computed tomography in a high-risk population of (ex-)smokers in Belgium. Lung Cancer. 2025;207:108697. https:\/\/doi.org\/10.1016\/j.lungcan.2025.108697.","journal-title":"Lung Cancer"},{"key":"15102_CR16","doi-asserted-by":"publisher","unstructured":"de Nijs K, Ten Haaf K, Moldovanu D, Hubert J, van den Bosch I, Eijkelboom A, et al. Influence of changing patterns in lung cancer treatment and survival on the cost-effectiveness of CT screening: a modeling study. EClinicalMedicine. 2025;88. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103446.","DOI":"10.1016\/j.eclinm.2025.103446"},{"key":"15102_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/1759-7714.13616","volume":"12","author":"A Buja","year":"2021","unstructured":"Buja A, Rivera M, De Polo A, di Brino E, Marchetti M, Scioni M, et al. Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole\u2010disease model. Thorac Cancer. 2021;12:13\u201320. https:\/\/doi.org\/10.1111\/1759-7714.13616.","journal-title":"Thorac Cancer"},{"key":"15102_CR18","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s40273-023-01291-6","volume":"41","author":"P Ngo","year":"2023","unstructured":"Ngo P, Karikios D, Goldsbury D, Wade S, Lwin Z, Hughes BG, et al. Development and validation of txSim: a model of advanced lung cancer treatment in Australia. PharmacoEconomics. 2023;41:1525\u201337. https:\/\/doi.org\/10.1007\/s40273-023-01291-6.","journal-title":"PharmacoEconomics"},{"key":"15102_CR19","unstructured":"National Cancer Registry. Cancer in Ireland 1994\u20132022: Annual statistical report [Internet]. National Cancer Registry Ireland. 2024. https:\/\/www.ncri.ie\/sites\/ncri\/files\/pubs\/NCRI_AnnualStatisticalReport_2022.pdf. Accessed 11 Feb 2026."},{"key":"15102_CR20","doi-asserted-by":"publisher","first-page":"S215","DOI":"10.1016\/j.jtho.2024.09.384","volume":"19","author":"DE O\u2019Reilly","year":"2024","unstructured":"O\u2019Reilly DE, Roche S, Toomey S, Hennessy B, Fitzmaurice GJ, Egan K, et al. P2.04A.04 The Lung Health Check Pilot: Ireland\u2019s Flagship Lung Cancer Screening Trial. J Thorac Oncol. 2024;19:S215. https:\/\/doi.org\/10.1016\/j.jtho.2024.09.384.","journal-title":"J Thorac Oncol"},{"key":"15102_CR21","doi-asserted-by":"publisher","first-page":"78985","DOI":"10.18632\/oncotarget.12587","volume":"7","author":"Y-L Zhang","year":"2016","unstructured":"Zhang Y-L, Yuan J-Q, Wang K-F, Fu X-H, Han X-R, Threapleton D, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7:78985. https:\/\/doi.org\/10.18632\/oncotarget.12587.","journal-title":"Oncotarget"},{"key":"15102_CR22","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jtho.2017.11.117","volume":"13","author":"I Letovanec","year":"2018","unstructured":"Letovanec I, Finn S, Zygoura P, Smyth P, Soltermann A, Bubendorf L, et al. Evaluation of NGS and RT-PCR methods for ALK rearrangement in European NSCLC patients: results from the European Thoracic Oncology Platform Lungscape Project. J Thorac Oncol. 2018;13:413\u201325. https:\/\/doi.org\/10.1016\/j.jtho.2017.11.117.","journal-title":"J Thorac Oncol"},{"key":"15102_CR23","unstructured":"Lung Cancer Foundation of America. What is ROS1-positive in lung cancer and how is it treated? [Internet]. Accessed 11 Feb 2026. https:\/\/lcfamerica.org\/about-lung-cancer\/diagnosis\/biomarkers\/ros1\/"},{"key":"15102_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades A, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9. https:\/\/doi.org\/10.1186\/1471-2288-12-9.","journal-title":"BMC Med Res Methodol"},{"key":"15102_CR25","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/nejmoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus Chemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell Lung Cancer. N Engl J Med. 2016;375:1823\u201333. https:\/\/doi.org\/10.1056\/nejmoa1606774.","journal-title":"N Engl J Med"},{"key":"15102_CR26","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/nejmoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non\u2013Small-Cell Lung Cancer. N Engl J Med. 2015;373:1627\u201339. https:\/\/doi.org\/10.1056\/nejmoa1507643.","journal-title":"N Engl J Med"},{"key":"15102_CR27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1471-2407-14-18","volume":"14","author":"H Akamatsu","year":"2014","unstructured":"Akamatsu H, Mori K, Naito T, Imai H, Ono A, Shukuya T, et al. Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy. BMC Cancer. 2014;14:18. https:\/\/doi.org\/10.1186\/1471-2407-14-18.","journal-title":"BMC Cancer"},{"key":"15102_CR28","unstructured":"Health Service Executive. ABF 2024 Admitted Patient Price List - Daycase Only [Internet]. https:\/\/assets.hse.ie\/media\/documents\/ABF_2024_Admitted_Patient_Price_List_-_Daycase_Only.pdf. Accessed 11 Feb 2026."},{"key":"15102_CR29","unstructured":"Health Service Executive. ABF 2024 Admitted Patient Price List - Inpatient Only [Internet]. https:\/\/assets.hse.ie\/media\/documents\/ABF_2024_Admitted_Patient_Price_List_-_Inpatient_Only.pdf. Accessed 11 Feb 2026."},{"key":"15102_CR30","unstructured":"Health Service Executive. Primary Care Reimbursement Service (PCRS) online services [Internet]. HSE.ie. https:\/\/healthservice.hse.ie\/staff\/benefits-and-services\/pcrs\/. Accessed 11 Feb 2026."},{"key":"15102_CR31","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1093\/pubmed\/fdac154","volume":"45","author":"GE Crealey","year":"2023","unstructured":"Crealey GE, Hackett C, Harkin K, Heckmann P, Kelleher F, Lyng \u00c1, et al. Melanoma-related costs by disease stage and phase of management in Ireland. J Public Health. 2023;45:714\u201322. https:\/\/doi.org\/10.1093\/pubmed\/fdac154.","journal-title":"J Public Health"},{"key":"15102_CR32","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jval.2012.04.014","volume":"15","author":"AH Briggs","year":"2012","unstructured":"Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD, et al. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. Value Health. 2012;15:835\u201342. https:\/\/doi.org\/10.1016\/j.jval.2012.04.014.","journal-title":"Value Health"},{"key":"15102_CR33","volume-title":"Decision modelling for health economic evaluation","author":"AH Briggs","year":"2011","unstructured":"Briggs AH, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford Univ. Press; 2011."},{"key":"15102_CR34","doi-asserted-by":"publisher","first-page":"e2512455","DOI":"10.1001\/jamanetworkopen.2025.12455","volume":"8","author":"M Zhao","year":"2025","unstructured":"Zhao M, Shao T, Yin Y, Fang H, Shao H, Tang W. Adverse Event Costs and Cost-Effectiveness Analyses of Anticancer Drugs: A Systematic Review. JAMA Netw Open. 2025;8:e2512455. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.12455.","journal-title":"JAMA Netw Open"},{"key":"15102_CR35","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1177\/0272989X12454579","volume":"32","author":"DM Eddy","year":"2012","unstructured":"Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model Transparency and Validation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20137. Med Decis Mak. 2012;32:733\u201343. https:\/\/doi.org\/10.1177\/0272989X12454579.","journal-title":"Med Decis Mak"},{"key":"15102_CR36","doi-asserted-by":"publisher","first-page":"100730","DOI":"10.1016\/j.ctarc.2023.100730","volume":"36","author":"NM Carroll","year":"2023","unstructured":"Carroll NM, Eisenstein J, Burnett-Hartman AN, Greenlee RT, Honda SA, Neslund-Dudas CM, et al. Uptake of novel systemic therapy: Real world patterns among adults with advanced non-small cell lung cancer. Cancer Treat Res Commun. 2023;36:100730. https:\/\/doi.org\/10.1016\/j.ctarc.2023.100730.","journal-title":"Cancer Treat Res Commun"},{"key":"15102_CR37","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00432-020-03414-4","volume":"147","author":"E Nadler","year":"2021","unstructured":"Nadler E, Arondekar B, Aguilar KM, Zhou J, Chang J, Zhang X, et al. Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study. J Cancer Res Clin Oncol. 2021;147:671\u201390. https:\/\/doi.org\/10.1007\/s00432-020-03414-4.","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-15102-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-15102-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-15102-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:38:57Z","timestamp":1791254337000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-026-15102-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15102"],"URL":"https:\/\/doi.org\/10.1186\/s12913-026-15102-z","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"4 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study used aggregate, publicly reported registry data and published literature. No individual patient-level data were accessed. Ethical approval was not required. No consent to participate was required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prof. Kathleen E. Bennett reports having received funding from industry partners Novartis and IQVIA within the past three years for projects unrelated to this work. All other authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1364"}}